$4.47 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 122 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | SAREPTA THERAPEUTICS INCdbcv 1.500%11/1 | $116,124,000 | – | 88,657,000 | +100.0% | 2.60% | – | |
| HZNP | New | HORIZON THERAPEUTICS PUB L | $48,923,000 | – | 465,000 | +100.0% | 1.09% | – |
| GILD | New | GILEAD SCIENCES INC | $45,508,000 | – | 765,489 | +100.0% | 1.02% | – |
| New | 1LIFE HEALTHCARE INCnote 3.000% 6/1 | $34,716,000 | – | 40,000,000 | +100.0% | 0.78% | – | |
| GDRX | New | GOODRX HLDGS INC | $18,926,000 | – | 979,106 | +100.0% | 0.42% | – |
| IMGN | New | IMMUNOGEN INC | $16,520,000 | – | 3,470,675 | +100.0% | 0.37% | – |
| New | OAK STR HEALTH INCnote 3/1 | $14,316,000 | – | 18,000,000 | +100.0% | 0.32% | – | |
| EOLS | New | EVOLUS INC | $13,792,000 | – | 1,229,234 | +100.0% | 0.31% | – |
| New | AN2 THERAPEUTICS INC | $8,803,000 | – | 584,136 | +100.0% | 0.20% | – | |
| INSM | New | INSMED INC | $7,157,000 | – | 304,572 | +100.0% | 0.16% | – |
| FHTX | New | FOGHORN THERAPEUTICS INC | $3,638,000 | – | 238,865 | +100.0% | 0.08% | – |
| SRSAW | New | SARISSA CAPITAL ACQUISITN CO*w exp 10/23/202 | $120,000 | – | 333,333 | +100.0% | 0.00% | – |
| SRSAU | New | SARISSA CAPITAL ACQUISITN COunit 10/23/2027 | $0 | – | 1 | +100.0% | 0.00% | – |
| MTACU | New | MEDTECH ACQUISITION CORPunit 12/18/2025 | $0 | – | 1 | +100.0% | 0.00% | – |
| EUCRU | New | EUCRATES BIOMEDICAL ACQU CORunit 10/23/2027 | $0 | – | 1 | +100.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
| 3 | 2024-02-01 |
| 4 | 2023-11-21 |
| 13F-HR | 2023-11-14 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.